DGIdb - ALPELISIB Drug Record

ALPELISIB chembl:CHEMBL2396661 ApprovedAntineoplastic

Alternate Names:

PIQRAY
NVP-BYL719
BYL-719
ALPELISIB
BYL719
BYL 719
chembl:CHEMBL2396661
chemidplus:1217486-61-7
pubchem.compound:56649450

Drug Info:

Pharmaceutical Developer	Novartis
Source Reported Drug Name(s)	BYL719
Drug Class	PI3K/mTOR dual Inhibitor
Drug Class	Kinase Inhibitors

(10 More Sources)

Publications:

Fritsch et al., 2014, Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials., Mol. Cancer Ther.
André F et al., 2019, Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer., N Engl J Med
Anderson et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med
Castel et al., 2016, PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition., Cancer Cell
Mayer et al., 2017, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer., Clin. Cancer Res.
Packer et al., 2017, PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers., Mol. Cancer Ther.
Le et al., 2016, Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer., Cancer Discov
Fernandes MS et al., 2016 Oct 18, Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers., Oncotarget
Bonelli et al., 2015, Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations., Mol. Cancer Ther.
Dogruluk et al., 2015, Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations., Cancer Res.
Chen IC et al., 2017, Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen., Sci Rep
Yang X et al., 2017, New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound., Sci Rep
Gritsman et al., 2014, Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α., J. Clin. Invest.
Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell
Schwartz et al., 2015, Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ., Cancer Cell
Juric et al., 2015, Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor., Nature
Herkert et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res.
Costa et al., 2015, Discovery and functional characterization of a neomorphic PTEN mutation., Proc. Natl. Acad. Sci. U.S.A.
Horn et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res.
Oddo et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res.
Vinik et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol
van Geel et al., 2017, A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer., Cancer Discov

ALPELISIB PI4KA

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ALPELISIB SGK1

Interaction Score: 1.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27451907

Sources:
CIViC
ALPELISIB PIK3CA

Interaction Score: 0.31

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type no benefit

combination therapy Alpelisib + WEHI-539

Approval Status Preclinical - Cell line xenograft

PMIDs:
24608574 31091374 27974663 27451907 27126994 28119489 27604488 27602501 26013318 26627007 28852212 29109464

Sources:
ClearityFoundationBiomarkers MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB
ALPELISIB PIK3R6

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB PIK3R4

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB PTEN

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
25544636 25409150 27604488 26577700 28119489 26504226

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
ALPELISIB PIK3R1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB RB1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25002028

Sources:
CIViC
ALPELISIB BRAF

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Alpelisib + PLX4720

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
27659046 27924459 28363909 26577700 27312529

Sources:
JAX-CKB CIViC
ALPELISIB CDK4

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25002028

Sources:
CIViC
ALPELISIB PIK3C3

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
ALPELISIB PIK3C2G

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
ALPELISIB PIK3C2A

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
ALPELISIB PIK3C2B

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
ALPELISIB PIK3R5

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB PIK3R3

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB PIK3R2

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB PIK3CD

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB NRAS

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
24569456

Sources:
JAX-CKB
ALPELISIB MAP2K1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
27312529

Sources:
JAX-CKB
ALPELISIB FGFR2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
28119489

Sources:
JAX-CKB
ALPELISIB PIK3CB

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB KRAS

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-263 + Alpelisib + CGM097 + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
27659046 27602501 24608574 27312529

Sources:
JAX-CKB
ALPELISIB HRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
ALPELISIB AKT1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27604488

Sources:
JAX-CKB
ALPELISIB FGFR1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Indication/Tumor Type estrogen-receptor positive breast cancer

PMIDs:
27126994

Sources:
JAX-CKB
ALPELISIB PIK3CG

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
ALPELISIB ESR2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ALPELISIB FGFR3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BGJ398 + BYL719

Indication/Tumor Type transitional cell carcinoma

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
ALPELISIB ERBB2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
ALPELISIB ESR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
ALPELISIB MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Lung

PMIDs:
None found

Sources:
CancerCommons
ALPELISIB TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-263 + Alpelisib + CGM097 + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
27659046

Sources:
JAX-CKB

MyCancerGenome: BYL719
- Version: 20-Jun-2017
Alternate Names:

BYL719 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
CancerCommons: BYL719
- Version: 25-July-2013
Alternate Names:

BYL719 PubChem Drug Name

56649450 PubChem Drug ID

BYL719 Drug Trade Name

Drug Info:

Drug Class PI3K/mTOR dual Inhibitor

Source Reported Drug Name(s) BYL719

Pharmaceutical Developer Novartis

Publications:

JAX-CKB: BYL719

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

van Geel et al., 2017, A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer., Cancer Discov

Oddo et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res.

Herkert et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res.

JAX-CKB: Alpelisib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Anderson et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med

Mayer et al., 2017, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer., Clin. Cancer Res.

Castel et al., 2016, PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition., Cancer Cell

CIViC: ALPELISIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell

André F et al., 2019, Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer., N Engl J Med

Fritsch et al., 2014, Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials., Mol. Cancer Ther.

TTD: BYL719
- Version: 2020.06.01
Alternate Names:

D0W7HE TTD Drug ID

Drug Info:

Publications:
FDA: Alpelisib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2396661
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: BYL719
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: BYL719
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: BYL719
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2396661
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
PharmGKB: alpelisib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
OncoKB: Alpelisib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:

Response Type	no benefit
combination therapy	Alpelisib + WEHI-539
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	prostate cancer
Response Type	sensitive
Approval Status	Preclinical - Cell culture

combination therapy	Alpelisib + PLX4720
Indication/Tumor Type	melanoma
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

combination therapy	ABT-263 + Alpelisib + CGM097 + Trametinib
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

combination therapy	BYL719 + MEK162
Indication/Tumor Type	ovarian cancer
Response Type	predicted – sensitive

Indication/Tumor Type	breast cancer
Response Type	resistant
Approval Status	Preclinical - Cell culture

combination therapy	BGJ398 + BYL719
Indication/Tumor Type	transitional cell carcinoma
Response Type	predicted – sensitive

BYL719	PubChem Drug Name
56649450	PubChem Drug ID
BYL719	Drug Trade Name

ALPELISIB Drug Record

ALPELISIB chembl:CHEMBL2396661 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27451907

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type no benefit combination therapy Alpelisib + WEHI-539 Approval Status Preclinical - Cell line xenograft

PMIDs: 24608574 31091374 27974663 27451907 27126994 28119489 27604488 27602501 26013318 26627007 28852212 29109464

Sources: ClearityFoundationBiomarkers MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type prostate cancer Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 25544636 25409150 27604488 26577700 28119489 26504226

Sources: ClearityFoundationBiomarkers JAX-CKB CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25002028

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Alpelisib + PLX4720 Indication/Tumor Type melanoma Response Type sensitive

PMIDs: 27659046 27924459 28363909 26577700 27312529

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25002028

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 24569456

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
27451907

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type no benefit

combination therapy Alpelisib + WEHI-539

Approval Status Preclinical - Cell line xenograft

PMIDs:
24608574 31091374 27974663 27451907 27126994 28119489 27604488 27602501 26013318 26627007 28852212 29109464

Sources:
ClearityFoundationBiomarkers MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
25544636 25409150 27604488 26577700 28119489 26504226

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
25002028

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Alpelisib + PLX4720

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
27659046 27924459 28363909 26577700 27312529

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
25002028

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
24569456

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
27312529

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
28119489

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-263 + Alpelisib + CGM097 + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
27659046 27602501 24608574 27312529

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB